RU2013106498A - Антигенные композиции папилломавируса человека е7 и их применение - Google Patents
Антигенные композиции папилломавируса человека е7 и их применение Download PDFInfo
- Publication number
- RU2013106498A RU2013106498A RU2013106498/10A RU2013106498A RU2013106498A RU 2013106498 A RU2013106498 A RU 2013106498A RU 2013106498/10 A RU2013106498/10 A RU 2013106498/10A RU 2013106498 A RU2013106498 A RU 2013106498A RU 2013106498 A RU2013106498 A RU 2013106498A
- Authority
- RU
- Russia
- Prior art keywords
- polypeptide
- seq
- polypeptide according
- amino acid
- hpv
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 11
- 241000701806 Human papillomavirus Species 0.000 title claims abstract 5
- 230000000890 antigenic effect Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 29
- 229920001184 polypeptide Polymers 0.000 claims abstract 27
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 12
- 239000000427 antigen Substances 0.000 claims abstract 8
- 102000036639 antigens Human genes 0.000 claims abstract 8
- 108091007433 antigens Proteins 0.000 claims abstract 8
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims abstract 5
- 239000002671 adjuvant Substances 0.000 claims abstract 5
- 108020004707 nucleic acids Proteins 0.000 claims abstract 5
- 102000039446 nucleic acids Human genes 0.000 claims abstract 5
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 5
- 239000003970 toll like receptor agonist Substances 0.000 claims abstract 5
- 239000002773 nucleotide Substances 0.000 claims abstract 4
- 125000003729 nucleotide group Chemical group 0.000 claims abstract 4
- 229940044601 receptor agonist Drugs 0.000 claims abstract 4
- 239000000018 receptor agonist Substances 0.000 claims abstract 4
- 102000002689 Toll-like receptor Human genes 0.000 claims abstract 3
- 108020000411 Toll-like receptor Proteins 0.000 claims abstract 3
- 230000028993 immune response Effects 0.000 claims abstract 3
- 101150013553 CD40 gene Proteins 0.000 claims abstract 2
- 241000341655 Human papillomavirus type 16 Species 0.000 claims abstract 2
- 102000006992 Interferon-alpha Human genes 0.000 claims abstract 2
- 108010047761 Interferon-alpha Proteins 0.000 claims abstract 2
- 108010037274 Member 9 Tumor Necrosis Factor Receptor Superfamily Proteins 0.000 claims abstract 2
- 102000011769 Member 9 Tumor Necrosis Factor Receptor Superfamily Human genes 0.000 claims abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims abstract 2
- 208000009608 Papillomavirus Infections Diseases 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims 2
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims 2
- 210000003679 cervix uteri Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 210000000436 anus Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 201000003565 cervix uteri carcinoma in situ Diseases 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 210000003899 penis Anatomy 0.000 claims 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 208000022159 squamous carcinoma in situ Diseases 0.000 claims 1
- 208000022625 uterine cervix carcinoma in situ Diseases 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
- 210000003905 vulva Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/708—Specific hybridization probes for papilloma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36475010P | 2010-07-15 | 2010-07-15 | |
| US61/364,750 | 2010-07-15 | ||
| PCT/CA2011/000823 WO2012006727A1 (en) | 2010-07-15 | 2011-07-15 | Human papillomavirus e7 antigen compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013106498A true RU2013106498A (ru) | 2014-08-20 |
Family
ID=45468847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013106498/10A RU2013106498A (ru) | 2010-07-15 | 2011-07-15 | Антигенные композиции папилломавируса человека е7 и их применение |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20130209402A1 (enExample) |
| EP (1) | EP2593548A4 (enExample) |
| JP (1) | JP5964298B2 (enExample) |
| KR (1) | KR20130142104A (enExample) |
| CN (1) | CN103119168A (enExample) |
| AU (1) | AU2011279365A1 (enExample) |
| BR (1) | BR112013000912A2 (enExample) |
| CA (1) | CA2805300A1 (enExample) |
| MX (1) | MX2013000584A (enExample) |
| NZ (1) | NZ606949A (enExample) |
| RU (1) | RU2013106498A (enExample) |
| WO (1) | WO2012006727A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107868127A (zh) * | 2016-09-28 | 2018-04-03 | 艾托金生物医药（苏州）有限公司 | 一种用于检测病理组织切片中癌蛋白表达的单克隆抗体 |
| CN109384848A (zh) * | 2017-08-10 | 2019-02-26 | 深圳市雅臣智能生物工程有限公司 | 抗人乳头瘤病毒和抗cd人源化的双靶向抗体及其组合物、制备方法和应用 |
| TW202308629A (zh) | 2021-04-28 | 2023-03-01 | 法商Ｅｎｙｏ製藥公司 | 使用fxr激動劑作為組合治療以增強tlr3激動劑之療效 |
| CN118599010B (zh) * | 2024-05-03 | 2025-06-27 | 武汉凯德基诺生物技术有限公司 | 一种hpv16/18/52治疗性疫苗、制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1732598A4 (en) * | 2003-12-31 | 2009-08-26 | Pharmexa Inc | TRIGGERING CELLULAR IMMUNE RESPONSES TO THE HUMAN PAPILLOVIRUS USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS |
| PL1576967T3 (pl) * | 2004-03-18 | 2008-03-31 | Pasteur Institut | Rekombinowane białko niosące epitopy ludzkiego wirusa brodawczaka wstawione w białko cyklazy adenylanowej lub jego fragment oraz jego zastosowania terapeutyczne |
| GB0413510D0 (en) * | 2004-06-16 | 2004-07-21 | Glaxosmithkline Biolog Sa | Vaccine |
| KR20070029254A (ko) * | 2004-06-16 | 2007-03-13 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | Ｈｐｖ 16과 ｈｐｖ 18 및 적어도 ｈｐｖ 31, 45 또는52로부터 선택된 또 다른 ｈｐｖ 유형에 대한 백신 |
| MX2008013488A (es) * | 2006-04-21 | 2008-10-30 | Transgene Sa | Vacuna de virus de papiloma basado en hpv-16 (virus de papiloma humano 16). |
| BRPI0712729A2 (pt) * | 2006-05-31 | 2013-07-02 | Nventa Biopharmaceuticals Corp | composiÇÕes hspe7 bioativas purificadas |
-
2011
- 2011-07-15 CN CN2011800431149A patent/CN103119168A/zh active Pending
- 2011-07-15 RU RU2013106498/10A patent/RU2013106498A/ru not_active Application Discontinuation
- 2011-07-15 EP EP20110806181 patent/EP2593548A4/en not_active Withdrawn
- 2011-07-15 US US13/810,352 patent/US20130209402A1/en not_active Abandoned
- 2011-07-15 KR KR1020137003874A patent/KR20130142104A/ko not_active Withdrawn
- 2011-07-15 WO PCT/CA2011/000823 patent/WO2012006727A1/en not_active Ceased
- 2011-07-15 BR BR112013000912A patent/BR112013000912A2/pt not_active IP Right Cessation
- 2011-07-15 CA CA2805300A patent/CA2805300A1/en not_active Abandoned
- 2011-07-15 AU AU2011279365A patent/AU2011279365A1/en not_active Abandoned
- 2011-07-15 MX MX2013000584A patent/MX2013000584A/es not_active Application Discontinuation
- 2011-07-15 NZ NZ606949A patent/NZ606949A/en not_active IP Right Cessation
- 2011-07-15 JP JP2013518914A patent/JP5964298B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| MX2013000584A (es) | 2013-09-26 |
| JP2013540421A (ja) | 2013-11-07 |
| EP2593548A1 (en) | 2013-05-22 |
| BR112013000912A2 (pt) | 2016-05-17 |
| CA2805300A1 (en) | 2012-01-19 |
| EP2593548A4 (en) | 2013-11-27 |
| CN103119168A (zh) | 2013-05-22 |
| KR20130142104A (ko) | 2013-12-27 |
| US20130209402A1 (en) | 2013-08-15 |
| JP5964298B2 (ja) | 2016-08-03 |
| NZ606949A (en) | 2015-11-27 |
| WO2012006727A1 (en) | 2012-01-19 |
| AU2011279365A1 (en) | 2013-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sasagawa et al. | Immune responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer | |
| Zhai et al. | Gardasil-9: A global survey of projected efficacy | |
| Schellenbacher et al. | Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses | |
| Stanley et al. | Host responses to infection with human papillomavirus | |
| Nunes et al. | Innate immunity and HPV: friends or foes | |
| Syrjänen et al. | HPV in head and neck cancer—30 years of history | |
| Kim et al. | Current status and future prospects for human papillomavirus vaccines | |
| Pouyanfard et al. | Minor capsid protein L2 polytope induces broad protection against oncogenic and mucosal human papillomaviruses | |
| WO2002090382A3 (fr) | Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications | |
| CA3167595A1 (en) | Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines | |
| Huber et al. | A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types | |
| Feoli‐Fonseca et al. | Human papillomavirus (HPV) study of 691 pathological specimens from Quebec by PCR‐direct sequencing approach | |
| Oumeslakht et al. | Worldwide genetic variations in high-risk human papillomaviruses capsid L1 gene and their impact on vaccine efficiency | |
| Gamboa-Hoil | Human papillomavirus in men | |
| JP2013540421A5 (enExample) | ||
| JP5964298B2 (ja) | ヒトパピローマウイルスｅ７抗原組成物およびその使用 | |
| Menzo et al. | Human papillomavirus infections: new perspectives for prevention and treatment | |
| CN114716560B (zh) | 一种人乳头瘤病毒18型嵌合蛋白及其用途 | |
| RU2377305C1 (ru) | Мукозальная вакцина для иммунотерапии заболеваний, обусловленных вирусами папилломы человека, и способ лечения с ее использованием (варианты) | |
| Singh et al. | Human Papillomavirus Mediated Cancer | |
| Ke et al. | Analysis of HPV Infection and its Genetic Subtypes among Women in Lhasa Area | |
| Uslimgazieva et al. | HUMAN PAPILLOMA VIRUS AND HUMAN PAPILLOMA VIRUS VACCINES | |
| Begum et al. | Distribution of High-risk Human papillomavirus genotypes among Woman with Cervical Precancerous Lesions Attending in Tertiary Care Hospital of Bangladesh: HPV Genotypes in Cervical Precancerous Lesions in Bangladesh | |
| Novak-Weekley et al. | Human Papillomaviruses | |
| REN et al. | The relationship between human papillomavirus genotypes and cervical lesions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20161012 |